130 related articles for article (PubMed ID: 12844533)
21. Genetics of motor neuron disease.
Van Den Bosch L; Timmerman V
Curr Neurol Neurosci Rep; 2006 Sep; 6(5):423-31. PubMed ID: 16928353
[TBL] [Abstract][Full Text] [Related]
22. [Experimental approach to the gene therapy of motor neuron disease with the use of genes hypoxia-inducible factors].
Ismailov ShM; Barykova IuA; Shmarov MM; Tarantul VZ; Barskov IV; Kucherianu VG; Brylev LV; Logunov DIu; Tutykhina IL; Bocharov EV; Zakharova MN; Naroditskiĭ BS; Illarioshkin SN
Genetika; 2014 May; 50(5):591-601. PubMed ID: 25715475
[TBL] [Abstract][Full Text] [Related]
23. Non-primate EIAV-based lentiviral vectors as gene delivery system for motor neuron diseases.
Azzouz M; Mazarakis N
Curr Gene Ther; 2004 Sep; 4(3):277-86. PubMed ID: 15384941
[TBL] [Abstract][Full Text] [Related]
24. Animal models for motor neuron disease.
Green SL; Tolwani RJ
Lab Anim Sci; 1999 Oct; 49(5):480-7. PubMed ID: 10551448
[TBL] [Abstract][Full Text] [Related]
25. RNA dysregulation in diseases of motor neurons.
Ibrahim F; Nakaya T; Mourelatos Z
Annu Rev Pathol; 2012; 7():323-52. PubMed ID: 22035195
[TBL] [Abstract][Full Text] [Related]
26. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation.
Peviani M; Salvaneschi E; Bontempi L; Petese A; Manzo A; Rossi D; Salmona M; Collina S; Bigini P; Curti D
Neurobiol Dis; 2014 Feb; 62():218-32. PubMed ID: 24141020
[TBL] [Abstract][Full Text] [Related]
27. Genetic background effects on disease onset and lifespan of the mutant dynactin p150Glued mouse model of motor neuron disease.
Heiman-Patterson TD; Blankenhorn EP; Sher RB; Jiang J; Welsh P; Dixon MC; Jeffrey JI; Wong P; Cox GA; Alexander GM
PLoS One; 2015; 10(3):e0117848. PubMed ID: 25763819
[TBL] [Abstract][Full Text] [Related]
28. Low dietary protein content alleviates motor symptoms in mice with mutant dynactin/dynein-mediated neurodegeneration.
Wiesner D; Sinniger J; Henriques A; Dieterlé S; Müller HP; Rasche V; Ferger B; Dirrig-Grosch S; Soylu-Kucharz R; Petersén A; Walther P; Linkus B; Kassubek J; Wong PC; Ludolph AC; Dupuis L
Hum Mol Genet; 2015 Apr; 24(8):2228-40. PubMed ID: 25552654
[TBL] [Abstract][Full Text] [Related]
29. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation.
Gurney ME; Pu H; Chiu AY; Dal Canto MC; Polchow CY; Alexander DD; Caliendo J; Hentati A; Kwon YW; Deng HX
Science; 1994 Jun; 264(5166):1772-5. PubMed ID: 8209258
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-6 Deficiency Does Not Affect Motor Neuron Disease Caused by Superoxide Dismutase 1 Mutation.
Han Y; Ripley B; Serada S; Naka T; Fujimoto M
PLoS One; 2016; 11(4):e0153399. PubMed ID: 27070121
[TBL] [Abstract][Full Text] [Related]
31. Adult-onset spinal muscular atrophy: An update.
Juntas Morales R; Pageot N; Taieb G; Camu W
Rev Neurol (Paris); 2017 May; 173(5):308-319. PubMed ID: 28456383
[TBL] [Abstract][Full Text] [Related]
32. Dysfunction in endoplasmic reticulum-mitochondria crosstalk underlies SIGMAR1 loss of function mediated motor neuron degeneration.
Bernard-Marissal N; Médard JJ; Azzedine H; Chrast R
Brain; 2015 Apr; 138(Pt 4):875-90. PubMed ID: 25678561
[TBL] [Abstract][Full Text] [Related]
33. Transgenic mice for interleukin 3 develop motor neuron degeneration associated with autoimmune reaction against spinal cord motor neurons.
Chavany C; Vicario-Abejón C; Miller G; Jendoubi M
Proc Natl Acad Sci U S A; 1998 Sep; 95(19):11354-9. PubMed ID: 9736740
[TBL] [Abstract][Full Text] [Related]
34. Genetic disorders of motor neurons.
Cole N; Siddique T
Semin Neurol; 1999; 19(4):407-18. PubMed ID: 10716663
[TBL] [Abstract][Full Text] [Related]
35. The neuroprotective factor Wlds does not attenuate mutant SOD1-mediated motor neuron disease.
Vande Velde C; Garcia ML; Yin X; Trapp BD; Cleveland DW
Neuromolecular Med; 2004; 5(3):193-203. PubMed ID: 15626820
[TBL] [Abstract][Full Text] [Related]
36. Inherited Paediatric Motor Neuron Disorders: Beyond Spinal Muscular Atrophy.
Teoh HL; Carey K; Sampaio H; Mowat D; Roscioli T; Farrar M
Neural Plast; 2017; 2017():6509493. PubMed ID: 28634552
[TBL] [Abstract][Full Text] [Related]
37. In vivo quantification of spinal and bulbar motor neuron degeneration in the G93A-SOD1 transgenic mouse model of ALS by T2 relaxation time and apparent diffusion coefficient.
Niessen HG; Angenstein F; Sander K; Kunz WS; Teuchert M; Ludolph AC; Heinze HJ; Scheich H; Vielhaber S
Exp Neurol; 2006 Oct; 201(2):293-300. PubMed ID: 16740261
[TBL] [Abstract][Full Text] [Related]
38. [Genetics of motor neuron disorders].
Corcia P; Praline J; Vourc'h P; Andres C
Rev Neurol (Paris); 2008 Feb; 164(2):115-30. PubMed ID: 18358870
[TBL] [Abstract][Full Text] [Related]
39. Neuropathology and omics in motor neuron diseases.
Tanaka F; Ikenaka K; Yamamoto M; Sobue G
Neuropathology; 2012 Aug; 32(4):458-62. PubMed ID: 22187969
[TBL] [Abstract][Full Text] [Related]
40. Candidate screening of the bovine and feline spinal muscular atrophy genes reveals no evidence for involvement in human motor neuron disorders.
Parkinson NJ; Baumer D; Rose-Morris A; Talbot K
Neuromuscul Disord; 2008 May; 18(5):394-7. PubMed ID: 18395445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
